AUTHENTICATED,
OHIO LEGISLATIVE SERVICE
COMMISSION
DOCUMENT #535556

Ohio Administrative Code

Rule 1301:18-11-01 Ohio Revised Code 928.031 Cannabinoids.

Effective: October 8, 2026

(A) Pursuant to division (A) section 928.031 of the Revised Code, the division of cannabis control, in consultation with the department of agriculture, hereby establishes the following lists of cannabinoids for purposes of section 928.01 of the Revised Code:

(1) Cannabinoids known to be capable of being naturally produced by a Cannabis sativa L. plant:

(a) Delta-9-tetrahydrocannabinol type:

(i) (−)-Δ9-trans-tetrahydrocannabinol;

(ii) (−)-Δ9-trans-tetrahydrocannabinolic acid A;

(iii) (−)-Δ9-trans-tetrahydrocannabinolic acid B;

(iv) (−)-Δ9-trans-tetrahydrocannabinol-C4;

(v) (−)-Δ9-trans-tetrahydrocannabinolic acid A-C4;

(vi) (−)-Δ9-trans-tetrahydrocannabivarin;

(vii) (−)-Δ9-trans-tetrahydrocannabivarinic acid;

(viii) (−)-Δ9-trans-tetrahydrocannabiorcol;

(ix) (−)-Δ9-trans-tetrahydrocannabiorcolic acid;

(x) (−)-Δ9-trans-tetrahydrocannabinal;

(xi) β-fenchyl (−)-Δ9-trans-tetrahydrocannabinolate;

(xii) α-fenchyl (−)-Δ9-trans-tetrahydrocannabinolate;

(xiii) Epi-bornyl (−)-Δ9-trans-tetrahydrocannabinolate;

(xiv) Bornyl (−)-Δ9-trans-tetrahydrocannabinolate;

(xv) α-terpenyl (−)-Δ9-trans-tetrahydrocannabinolate;

(xvi) 4-terpenyl (−)-Δ9-trans-tetrahydrocannabinolate;

(xvii) α-cadinyl (−)-Δ9-trans-tetrahydrocannabinolate;

(xviii) Y-eudesmyl (−)-Δ9-trans- tetrahydrocannabinolate;

AUTHENTICATED,
OHIO LEGISLATIVE SERVICE
COMMISSION
DOCUMENT #535556

(xix) 8α-hydroxy-(−)-Δ9-trans-tetrahydrocannabinol;

(xx) 8β-hydroxy-(−)-Δ9-trans-tetrahydrocannabinol;

(xxi) 11-acetoxy- (−)-Δ9-trans-tetrahydrocannabinolic acid A;

(xxii) 8-oxo-(−)-Δ9-trans-tetrahydrocannabinol;

(xxiii) Cannabisol;

(xxiv) (−)-Δ9-trans-tetrahydrocannabiphorol;

(xxv) (−)-Δ9-trans-tetrahydrocannabihexol.

(b) Delta-8-tetrahydrocannabinol type:

(i) (−)-Δ8-trans-tetrahydrocannabinol;

(ii) Δ8- trans-tetrahydrocannabinolic acid A;

(iii) 10α-hydroxy-Δ8-tetrahydrocannabinol;

(iv) 10β-hydroxy-Δ8-tetrahydrocannabinol; and

(v) 10a-α-hydroxy-10-oxo-Δ8-tetrahydrocannabinol.

(c) Cannabigerol type:

(i) cannabigerol;

(ii) Cannabigerolic acid;

(iii) Cannabigerolic acid monomethyl ether;

(iv) Cannabigerol monomethyl ether;

(v) Cannabigerovarin;

(vi) Cannabigerovarinic acid;

(vii) Cannabinerolic acid;

(viii) 5-acetyl-4-hydroxy-cannabigerol;

(ix) Y-eudesmyl-cannabigerolate;

AUTHENTICATED,
OHIO LEGISLATIVE SERVICE
COMMISSION
DOCUMENT #535556

(x) α-cadinyl-cannabigerolate;

(xi) (±)-6,7-trans-epoxycannabigerolic acid;

(xii) (±)-6,7-cis-epoxycannabigerolic acid;

(xiii) (±)-6,7-cis-epoxycannabigerol;

(xiv) (±)-6,7-trans-epxoycannabigerol;

(xv) Camagerol; and

(xvi) Sesquicannabigerol.

(d) Cannabichromene type:

(i) Cannabichromene;

(ii) Cannabichromenic acid;

(iii) Cannabivarichromene;

(iv) Cannabichromevarin;

(v) Cannabichromevarinic acid;

(vi) 2-methyl-2-(4-methyl-2-pentyl)-7-propyl-2H-1-benzopyran-5-ol;

(vii) (±)-4-acetoxycannabichromene;

(viii) (±)-3″-hydroxy-Δ4″-cannabichromene; and

(ix) (−)-7-hydroxycannabichromane.

(e) Cannabidiol type:

(i) Cannabidiol;

(ii) Cannabidiolic acid;

(iii) Cannabidiol monomethylether;

(iv) Cannabidiol-C4;

(v) (-)-Cannabidivarin;

AUTHENTICATED,
OHIO LEGISLATIVE SERVICE
COMMISSION
DOCUMENT #535556

(vi) Cannabidivarinic acid;

(vii) Cannabidiorcol;

(viii) Cannabidihexol;

(ix) Cannabidiphorol; and

(x) Cannabitwinol.

(f) Cannabinodiol type:

(i) Cannabinodiol; and

(ii) Cannabinodivirin.

(g) Cannabielsoin type:

(i) Cannabielsoin;

(ii) Cannabielsoin acid A;

(iii) Cannabielsoin acid B;

(iv) Cannabielsoin-C3; and

(v) Cannabielsoic acid B-C3.

(h) Cannabicyclol type:

(i) Cannabicyclol;

(ii) Cannabicyclolic acid; and

(iii) Cannabicyclovarin.

(i) Cannabinol type:

(i) Cannabinol;

(ii) Cannabinolic acid;

(iii) Cannabibutol;

(iv) Cannabivarin;

AUTHENTICATED,
OHIO LEGISLATIVE SERVICE
COMMISSION
DOCUMENT #535556

(v) Cannabinol-C2;

(vi) Cannabiorcol;

(vii) 1′S-hydroxy-cannabinol;

(viii) Cannabinol methylether;

(ix) 4-terpenyl cannabinolate;

(x) 8-hydroxycannabinol; and

(xi) 8-hydroxy cannabinolic acid A.

(j) Cannabitriol type:

(i) Cannabitriol;

(ii) (+)-Cannabitriol

(iii) (±)-cis-Cannabitriol;

(iv) Trans-cannabitriol ethyl ether;

(v) Trans-cannabitriol-C3;

(vi) Cannabitriol-C3;

(vii) (−)-trans-cannabitriol-OEt-C3;

(viii) 8-OH-cannabitriol-C5; and

(ix) Cannabidiolic acid A cannabitriol ester.

(k) Miscellaneous type:

(i) Dehydrocannabifuran;

(ii) Cannabifuran;

(iii) 8-hydroxy-isohexahydrocannabivirin;

(iv) 10-oxo-Δ6a(10a)-tetrahydrocannabinol;

(v) Cannabicitran;

AUTHENTICATED,
OHIO LEGISLATIVE SERVICE
COMMISSION
DOCUMENT #535556

(vi) (-)-Δ9-cis-(6aS,10aR)-tetrahydrocannabinol;

(vii) Cannabicoumaronone;

(viii) Cannabiripsol;

(ix) Cannabitetrol;

(x) Cannabichromanone-C5;

(xi) Cannabichromanone-C3;

(xii) (±)-Δ7-cis-isotetrahydrocannabivarin-C3;

(xiii) (-)-Δ7-trans-(1R,3R,6R)-isotetrahydrocannabivarin-C3;

(xiv) (-)-Δ7-trans-(1R,3R,6R)-isotetrahydrocannabinol-C5;

(xv) Cannabichromanone B;

(xvi) Cannabichromanone C;

(xvii) Cannabichromanone D;

(xviii) (-)-(7R)-cannabicoumarononic acid;

(xix) 4-acetoxy-2-geranyl-5-hydroxy-3-n-pentylphenol;

(xx) 2-geranyl-5-hydroxy-3-n-pentyl-1,4- benzoquinone;

(xxi) 5-acetoxy-6-geranyl-3-n-pentyl-1,4- benzoquinone;

(xxii) Cannabimovone;

(xxiii) Cannabioxepane;

(xxiv) 10α-hydroxy-Δ9,11-hexahydrocannabinol;

(xxv) 9β,10β-epoxyhexahydrocannabinol;

(xxvi) 9α-hydroxyhexahydrocannabinol;

(xxvii) 7-oxo-9α-hydroxyhexa-hydrocannabinol;

(xxviii) 10α-hydroxyhexahydrocannabinol;

AUTHENTICATED,
OHIO LEGISLATIVE SERVICE
COMMISSION
DOCUMENT #535556

(xxix) 10aR-hydroxyhexahydrocannabinol;

(xxx) 9α-hydroxy-10-oxo-Δ6a,10a-tetrahydrocannabinol.

(2) Tetrahydrocannabinol class cannabinoids known to be naturally occurring in the plant Cannabis sativa L.:

(a) (−)-Δ9-trans-tetrahydrocannabinol;

(b) (−)-Δ9-trans-tetrahydrocannabinolic acid A;

(c) (−)-Δ9-trans-tetrahydrocannabinolic acid B;

(d) (−)-Δ9-trans-tetrahydrocannabinol-C4;

(e) (−)-Δ9-trans-tetrahydrocannabinolic acid A-C4;

(f) (−)-Δ9-trans-tetrahydrocannabivarin;

(g) (−)-Δ9-trans-tetrahydrocannabivarinic acid;

(h) (−)-Δ9-trans-tetrahydrocannabiorcol;

(i) (−)-Δ9-trans-tetrahydrocannabiorcolic acid;

(j) (−)-Δ9-trans-tetrahydrocannabinal;

(k) 8α-hydroxy-(−)-Δ9-trans-tetrahydrocannabinol;

(l) 8β-hydroxy-(−)-Δ9-trans-tetrahydrocannabinol;

(m) 11-acetoxy- (−)-Δ9-trans-tetrahydrocannabinolic acid A;

(n) 8-oxo-(−)-Δ9-trans-tetrahydrocannabinol;

(o) Cannabisol;

(p) (−)-Δ9-trans-tetrahydrocannabiphorol;

(q) (−)-Δ9-trans-tetrahydrocannabihexol;

(r) (−)-Δ8-trans-tetrahydrocannabinol;

(s) Δ8- trans-tetrahydrocannabinolic acid A;

(t) 10α-hydroxy-Δ8-tetrahydrocannabinol;

AUTHENTICATED,
OHIO LEGISLATIVE SERVICE
COMMISSION
DOCUMENT #535556

(u) 10β-hydroxy-Δ8-tetrahydrocannabinol; and

(v) 10a-α-hydroxy-10-oxo-Δ8-tetrahydrocannabinol.

(3) All other known cannabinoids with similar effects to, or marketed to have similar effects to, tetrahydrocannabinol class cannabinoids:

(a) Delta-10-tetrahydrocannabinol and its isomers;

(b) Delta-7-tetrahydrocannabinol and its isomers;

(c) Delta-6a,10a-tetrahydrocannabinol and its isomers;

(d) Exo-tetrahydrocannabinol;

(e) Metabolites of tetrahydrocannabinol, including 11- hydroxy-tetrahydrocannabinol, 3'-hydroxy- tetrahydrocannabinol and 7-hydroxy-delta- tetrahydrocannabinol;

(f) Hydrogenated forms of tetrahydrocannabinol, including hexahydrocannabinol, hexahydrocannabiphorol and hexahydrocannabihexol;

(g) Synthetic forms of tetrahydrocannabinol as defined or named in rule 4729:9-1-01 of the Administrative Code;

(h) Ester forms of tetrahydrocannabinol, including delta-8-tetrahydrocannabinol-O-acetate, delta-9- tetrahydrocannabinol-O-acetate and hexahydrocannabinol-O-acetate;

(i) Varin forms of tetrahydrocannabinol, including delta-8-tetrahydrocannabivarin but excluding delta-9-tetrahydrocannabivarin;

(j) Analogs of tetrahydrocannabinols with an alkyl chain of four or more carbon atoms, including tetrahydrocannabiphorols, tetrahydrocannabioctyls, tetrahydrocannabihexols and tetrahydrocannabutols;

(k) (+)-Δ9-trans-tetrahydrocannabinol;

(l) (+)-Δ9-cis-tetrahydrocannabinol; and

(m) (-)-Δ9-cis-tetrahydrocannabinol.

(4) Any additional cannabinoids that have similar effects, or are marketed to have similar effects, on humans or animals as a tetrahydrocannabinol:

AUTHENTICATED,
OHIO LEGISLATIVE SERVICE
COMMISSION
DOCUMENT #535556

(a) Delta-10-tetrahydrocannabinol and its isomers;

(b) Delta-7-tetrahydrocannabinol and its isomers;

(c) Delta-6a,10a-tetrahydrocannabinol and its isomers;

(d) Exo-tetrahydrocannabinol;

(e) Metabolites of tetrahydrocannabinol, including 11-hydroxy- tetrahydrocannabinol, 3'-hydroxy-tetrahydrocannabinol and 7-hydroxy-delta-tetrahydrocannabinol;

(f) Hydrogenated forms of tetrahydrocannabinol, including hexahydrocannabinol, hexahydrocannabiphorol and hexahydrocannabihexol;

(g) Ester forms of tetrahydrocannabinol, including delta-8- tetrahydrocannabinol-O-acetate, delta-9- tetrahydrocannabinol-O-acetate and hexahydrocannabinol-O- acetate;

(h) Varin forms of tetrahydrocannabinol, including delta-8- tetrahydrocannabivarin but excluding delta-9- tetrahydrocannabivarin;

(i) Analogs of tetrahydrocannabinols with an alkyl chain of four or more carbon atoms, including tetrahydrocannabiphorols, tetrahydrocannabioctyls, tetrahydrocannabihexols and tetrahydrocannabutols;

(j) (+)-Δ9-trans-tetrahydrocannabinol;

(k) (+)-Δ9-cis-tetrahydrocannabinol;

(l) (-)-Δ9-cis-tetrahydrocannabinol;

(m) Δ8-isotetrahydrocannabinol and Δ4(8)- Isotetrahydrocannabinol;

(n) (6aR,9R)- Δ10-tetrahydrocannabinol; and

(o) Synthetic cannabinoids and cannabinoid pharmacophores as defined or named in rule 4729:9-1-01 of the Administrative Code, including, but not limited to the following:

(i) 9-(hydroxymethyl)-6,6-dimethy l-3-(2-methyloctan-2-yl)- 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol 7370;

AUTHENTICATED,
OHIO LEGISLATIVE SERVICE
COMMISSION
DOCUMENT #535556

(ii) (6aR,10aR)-3-(2-methyl-6-bromohex-2-yl)-6,6,9-t rimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol.;

(iii) 4-[4-(1,1-dimethylheptyl)-2,6-dimethoxyphenyl]-6,6-dimethyl-bicyclo[3.1.1] hept-2-ene-2-methanol;

(iv) 3-hydroxy-2-[(1R,6R)-3-methyl-6-(1-methylethenyl)-2- cyclohexen-1-yl]-5-pentyl-2,5-cyclohexadiene-1,4-dione;

(v) Naphthoylpyrroles. Any compound containing a 3-(1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent;

(vi) Naphthylmethylindoles. Any compound containing a 1H-indol- 3-yl-(1-naphthyl)methane structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent;

(vii) Naphthoylindoles. Any compound containing a 3-(1- naphthoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent;

(viii) Benzoylindoles. Any compound containing a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4- morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent;

(ix) Adamantoylindoles. Any compound containing a 3-(1-adamantoyl)indole structure with substitution at the nitrogen atom of the indole ring by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl

AUTHENTICATED,
OHIO LEGISLATIVE SERVICE
COMMISSION
DOCUMENT #535556

or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the adamantyl ring system to any extent;

(x) Cyclohexylphenols. Any compound containing a 2-(3- hyd roxycyclohexyl)phenol structure with substitution at the 5-position of the phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not substituted in the cyclohexyl ring to any extent;

(xi) Phenylacetylindoles. Any compound containing a 3-phenylacetylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent;

(xii) Naphthylmethylindenes. Any compound containing a naphthylideneindene structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent;

(xiii) 1-[2-(4-Morpholinyl)ethyl]-3-(1-napthoyl)indole;

(xiv) 5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol;

(xv) 5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol;

(xvi) 1-Pentyl-3-(1-napthoyl)indole;

(xvii) 1-Butyl-3-(1-napthoyl)indole;

(xviii) N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide;

(xix) 1-pentyl-1H-indol-3-yl(2,2,3,3-tetramethylcyclopropyl) methanone;

(xx) 1-(5-fluoro-pentyl)-1H-indol-3-yl)(2,2,3,3- tetramethylcyclopropyl) methanone;

AUTHENTICATED,
OHIO LEGISLATIVE SERVICE
COMMISSION
DOCUMENT #535556

(xxi) Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate;

(xxii) Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3 carboxylate;

(xxiii) N-(1-amino-3-methyl-1-oxobutan-2-yl-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide;

(xxiv) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H- indazole-3-carboxamide;

(xxv) Indole - 3-ylcycloalkyl ketones. Any compound containing an Indole-3-ylcycloalkyl ketone structure with substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, (1-(N-methyl-2- piperidinyl)methyl, (tetrahydro-2H-pyran-4-yl)methyl or (morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent or whether or not substituted at the cycloalkyl ring to any extent;

(xxvi) Quinolinyl-indole carboxylates. Any compound containing a quinolinyl-indole-3-carboxylate structure with substitution of the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, (1-(N-methyl-2- piperidinyl)methyl, (tetrahydro-2H-pyran-4-yl)methyl or (morpholinyl) ethyl group, whether or not further substituted in the indole ring or quinolinyl structure to any extent;

(xxvii) 1-napthalenyl[4-(pentylox)-1-napthalenyl]-methanone;

(xxviii) [(6S,6aR, 9R,10aR)-9-hydroxy-6-methyl-3-[(2R)-5- phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a- octahydrophenanthridin-1-yl] acetate;

(xxix) 3-dimethylheptyl-11-hydroxyhexahydrocannabinol;

(xxx) N-cyclopropyl-8-[3-(1,1-dimethylheptyl)-5-hydroxyphenoxy]-octanamide;

(xxxi) N-cyclopropyl-11-(3-hydroxy-5-pentylphenoxy)-undecanamide;

(xxxii) N-cyclopropyl-11-(2-hexyl-5-hydroxyphenoxy)-undecanamide;

(xxxiii) Indazole-3-carboxamides. Any compound containing an Indazole-3-carboxamide structure with substitution at the nitrogen atom of the indazole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, (1-(N-methyl-2- piperidinyl)methyl, (tetrahydro-2H-

AUTHENTICATED,
OHIO LEGISLATIVE SERVICE
COMMISSION
DOCUMENT #535556

pyran-4-yl)methyl or (morpholinyl) ethyl group, whether or not further substituted in the indole ring to any extent;

(xxxiv) Indole -3-carboxamides. Any compound containing an Indole-3-carboxamide structure with substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, (1-(N-methyl-2-piperidinyl)methyl, (tetrahydro- 2H-pyran-4-yl)methyl or (morpholinyl) ethyl group, whether or not further substituted in the indole ring to any extent;

(xxxv) methanandamide, including (5Z,8Z,11Z,14Z)--[(1R)-2-hydroxy-1-methylethyl]icosa-5,8,11,14-tetraenamide and arachidonyl- 1'-hydroxy-2'-propylamide;

(xxxvi) (6aR,10aR)-3-(1-adamantyl)-6,6,9-trimethyl-6 a,7,10,10a- tetrahydrobenzo[c]chromen-1-ol;

(xxxvii) (4aR,12bR)-8-hexyl-2,5,5-trimethyl-1,4,4a,8,9,10,11,12b-octahydronaphtho[3,2-c]isochromen-12-ol;

(xxxviii) (6aR,9R,10aR)-3-[(E)-hept-1-enyl]-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-1-ol;

(xxxix) (6aR,9R,10aR)-3-[(Z)-hept-1-enyl]-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-1-ol;

(xl) (6aR,9R,10aR)-3-(1-hexyl-cyclobut-1-yl)-6 a,7,8,9,10,10a-hexahydro-6,6-dimethyl-6H-dibenzo[b,d]pyran-1,9 diol;

(xli) (-)-(R)-3-(2-Hydroxymethylindanyl-4-o xy)phenyl-4,4,4- trifluorobutyl-1-sulfonate;

(xlii) (6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,10,10a-tetrahydro-1H-benzo[c]chromene-1,4(6H)-dione;

(xliii) N-(benzol[1,3]dioxol-5-ylmethyl)-7-methoxy-2-oxo-8- pentyloxy-1,2-dihydroquinoline-3-carboxamide;

(xliv) ((6aR,10aR)-6,6-dimethyl-3-(2-methyloctan-2-y l)-6a,7,10,10a- tetrahydrobenzo[c]chromen-9-yl)methano;

(xlv) (6aR,10aR)-3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro- 6,6,9-trimethyl-6H-Dibenzo[b,d]pyran;

AUTHENTICATED,
OHIO LEGISLATIVE SERVICE
COMMISSION
DOCUMENT #535556

(xlvi) (6aR,10aR)-3-(1,1-dimethylbutyl)-6a,7,10,10a-tetrahydro - 6,6,9-trimethyl-6H-dibenzo[b,d]pyran;

(xlvii) (6aR,10aR)- 1-methoxy- 6,6,9-trimethyl- 3-[(2R)-1,1,2-trimethylbutyl]- 6a,7,10,10a-tetrahydrobenzo[c]chromene;

(xlviii) [3-(3-carbamoylphenyl)phenyl]-N-cyclohexylcarbamate;

(xlix) [1,1'-biphenyl]-3-yl-carbamic acid, cyclohexyl ester; OR cyclohexyl [1,1'-biphenyl]-3-ylcarbamate;

(l) 6-methyl-2-[(4-methylphenyl)amino]-4H-3,1-b enzoxazin-4- one;

(li) 3'-carbamoyl-6-hydroxy-[1,1'-biphenyl]-3-yl cyclohexylcarbamate;

(lii) (R)-(+)-[2,3-dihydro-5-methyl-3 -(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1 - napthalenylmethanone and [2,3-dihydro-5-methyl-3-(4-morp holinylmethyl)pyrrolo[(1,2,3-de)-1,4-benzoxazin-6-yl]-1-napthalenylmethanone;

(liii) Cyclopropanoylindoles; and

(liv) Tetramethylcyclopropane-thiazole carboxamides.